PMID- 27957325
OWN - NLM
STAT- MEDLINE
DCOM- 20180730
LR  - 20240325
IS  - 2050-4527 (Print)
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 4
IP  - 2
DP  - 2016 Jun
TI  - Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human 
      primates.
PG  - 135-147
AB  - The anti-human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair(R), 
      Genentech, South San Fransisco, CA), is effective in the treatment of poorly 
      controlled moderate to severe allergic asthma and chronic idiopathic urticaria. 
      It acts by specifically binding to the constant domain (Cϵ3) of free human IgE in 
      the blood and interstitial fluid. Although efficacious, use of omalizumab is 
      limited due to restrictions on patient weight and pre-existing IgE levels, and 
      frequent dosing (q2-4 weeks). A vaccine inducing anti-IgE antibodies has the 
      potential for similar clinical benefits with less frequent dosing and relatively 
      lower cost of goods. We developed a vaccine containing two IgE peptide-conjugates 
      targeting the Cϵ3 domain of human IgE. As part of preclinical evaluation of the 
      vaccine to optimize formulation and dose prior to initiating clinical studies, we 
      evaluated the vaccine in non-human primates, and demonstrate the induction of 
      anti-peptide antibodies that can bind to conformationally intact human IgE and 
      are capable, at least in some animals, of substantial lowering circulating IgE 
      levels.
FAU - Weeratna, Risini D
AU  - Weeratna RD
AD  - Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada.
FAU - Chikh, Ghania
AU  - Chikh G
AD  - Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada.
FAU - Zhang, Lu
AU  - Zhang L
AD  - Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada.
FAU - Fraser, James D
AU  - Fraser JD
AD  - Pfizer Vaccine Immunotherapeutics La Jolla California USA.
FAU - Thorn, Jennifer M
AU  - Thorn JM
AD  - Pfizer Biotherapeutics Pharmaceutical Sciences St. Louis Missouri USA.
FAU - Merson, James R
AU  - Merson JR
AD  - Pfizer Biotherapeutics Pharmaceutical Sciences St. Louis Missouri USA.
FAU - McCluskie, Michael J
AU  - McCluskie MJ
AD  - Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada.
FAU - Champion, Brian R
AU  - Champion BR
AD  - Pfizer Vaccine Immunotherapeutics La Jolla California USA.
FAU - Davis, Heather L
AU  - Davis HL
AD  - Pfizer Vaccine Immunotherapeutics Ottawa Laboratories Ottawa Ontario Canada.
LA  - eng
PT  - Journal Article
DEP - 20160401
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Vaccines, Conjugate)
RN  - 0 (anti-IgE antibodies)
RN  - 2P471X1Z11 (Omalizumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Anti-Idiotypic/*immunology
MH  - Antibodies, Monoclonal
MH  - *Antibodies, Monoclonal, Humanized
MH  - Asthma/therapy
MH  - Humans
MH  - Omalizumab
MH  - Primates
MH  - Urticaria/therapy
MH  - Vaccines, Conjugate/*immunology
PMC - PMC4879460
OTO - NOTNLM
OT  - Allergy
OT  - IgE
OT  - IgE peptide conjugates
OT  - anti-IgE antibodies
OT  - vaccine
EDAT- 2016/12/14 06:00
MHDA- 2018/07/31 06:00
PMCR- 2016/04/01
CRDT- 2016/12/14 06:00
PHST- 2015/12/21 00:00 [received]
PHST- 2016/01/06 00:00 [revised]
PHST- 2016/01/12 00:00 [accepted]
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
PHST- 2016/04/01 00:00 [pmc-release]
AID - IID398 [pii]
AID - 10.1002/iid3.98 [doi]
PST - epublish
SO  - Immun Inflamm Dis. 2016 Apr 1;4(2):135-147. doi: 10.1002/iid3.98. eCollection 
      2016 Jun.